Parabilis Medicines, Inc. (PBLS)

Parabilis Medicines Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Income Operating Income Growth	-171.54	-147.85	-121.96
Net Income Net Income Growth	-231.67	-186.93	-161.48
Earnings Per Share EPS Growth	-23.45	-60.04	-54.25
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	1,121	27.71	87.98
Total Debt Total Debt Growth	47.51	58.7	66.2
Net Cash (Debt) Net Cash Growth	1,073	-30.99	21.78
Net Cash Growth	-	-	-
Net Cash Per Share Net Cash Per Share Growth	108.61	-9.95	7.32

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-111.29	-123.71	-103.61
Capital Expenditures CapEx Growth	-1.2	-0.31	-0.88
Free Cash Flow Free Cash Flow Growth	-112.49	-124.02	-104.49
Free Cash Flow Growth	-	-	-

Data Source: S&P Global Market Intelligence Last updated: May 19, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 18, 2026

Data Sources Report a data error